Respiratory biotech Pulmatrix has completed its nontraditional path to the public markets, closing a merger with upstart Ruthigen to inherit a Nasdaq listing, at the same time banking $10 million and partnering up with generics giant Mylan.
A group of FDA advisers backed GlaxoSmithKline's latest asthma treatment for use in adults but balked at recommending it for adolescents, setting the stage for a likely approval in the fall.
Makers of respiratory drugs have been cutting prices as they vie for prime formulary positioning with payers. Boehringer's Spiriva has already taken a sales hit as a result, but now, the German pharma is hoping new combo med Stiolto can turn things around.
Boehringer Ingelheim picked up FDA approval for a next-generation COPD treatment, looking to contend for a share of the fast-crowding market for combination therapies.
Novartis, working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.
Remote patient monitoring startup Sentrian has partnered with the Scripps Translational Science Institute to study 1,000 chronic obstructive pulmonary disease (COPD) patients. The one-year study will use biosensors to continuously monitor patients and analyze that data to offer alerts for any deterioration. The intention is to intervene before an even becomes acute and requires hospitalization.
An app compatible with Apple's HealthKit launched a pilot program with New York City's Icahn School of Medicine at Mount Sinai, in attempt to help patients self-manage COPD.
The European Respiratory Society and American Thoracic Society have joined forces to highlight what we don't know about COPD in order to steer future research programs in the right way.
Pleasanton, CA's Spirometrix raised $8.6 million in funding for a sensor to detect and treat asthma and COPD, in a round led by Japan's NGK Spark Plugs, which gave $5 million.
Data from a study on a new nondrug treatment for chronic obstructive pulmonary disease offered evidence that Trudell Medical's Aerobika OPEP hand-held device is beneficial for COPD patients with recurring mucus buildup.